ANAB - Company ID 0001370053
The table below shows ANAPTYSBIO, INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $25.56M | $76.32M | $22.26M | $27.77M | $30.02M | $10.97M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | $31.41M | $37.82M | $41.18M | $42.21M | $42.00M |
ANAPTYSBIO, INC reported annual revenue of $234.60M for fiscal year 2025. That is up 157.0% from $91.28M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $16.68M (FY 2016) to $234.60M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $26.20M |
| $10.21M |
| $10.61M |
| $14.13M |
| $10.56M |
| $9.29M |
| Operating income | -$34.64M | $34.70M | -$26.17M | -$27.54M | -$22.76M | -$40.32M |
| Income tax | $40.00K | $0.00 | $39.00K | $44.00K | $0.00 | $9.00K |
| Net income | -$52.88M | $15.11M | -$38.63M | -$39.33M | -$32.85M | -$46.66M |
| EPS (diluted) | -$1.84 | $0.52 | -$1.34 | -$1.28 | -$1.14 | -$1.71 |